{
    "clinical_study": {
        "@rank": "15036", 
        "arm_group": [
            {
                "arm_group_label": "Glutamine", 
                "arm_group_type": "Active Comparator", 
                "description": "Powdered Glutamine, 10.0 grams by mouth TID for 30 days, so that daily dose is 30 grams per day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Powdered Dextrose, 8.33 grams by mouth TID for 30 days, so that daily dose is 25 grams per day"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a single-centered, double-blind, two-arm randomized study to determine if oral\n      glutamine will reduce radiation toxicity for the subjects undergoing Breast Conserving\n      Therapy."
        }, 
        "brief_title": "Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast Conserving Therapy", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Radiation Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject have been diagnosed with Stage I or II invasive breast cancer\n\n          -  Subject will undergo APBI as part of BCT\n\n          -  Subject is eligible for APBI based on ASTRO (American Society of Therapeutic\n             Radiation Oncology) criteria\n\n          -  Subject is 18 years of age or older\n\n          -  Subject is female\n\n        Exclusion Criteria:\n\n          -  History of uncontrolled, clinically significant lung, heart, endocrine, liver, or\n             renal disease\n\n          -  Subject has been diagnosed with any other cancer\n\n          -  Subject has a known hypersensitivity reaction to the following: GLN, glutamate, MSG\n             (i.e., Chinese restaurant syndrome)\n\n          -  Subject has history of collagen vascular disease\n\n          -  Subject has been diagnosed with Diabetes mellitus I or II\n\n          -  Subject has had any prior breast radiation\n\n          -  Subject is pregnant or breastfeeding"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012608", 
            "org_study_id": "202253"
        }, 
        "intervention": [
            {
                "arm_group_label": "Glutamine", 
                "description": "Oral glutamine for subjects undergoing breast conserving therapy", 
                "intervention_name": "Glutamine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Gln", 
                    "Q"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "For subjects undergoing breast conserving therapy", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Dextrose", 
                    "Dextrose monohydrate", 
                    "Sugar"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "breast", 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "contact": {
                "email": "dewade@uams.edu", 
                "last_name": "Daisy E Wade, CCRP", 
                "phone": "501-686-8274"
            }, 
            "facility": {
                "address": {
                    "city": "Little Rock", 
                    "country": "United States", 
                    "state": "Arkansas", 
                    "zip": "72205"
                }, 
                "name": "University of Arkansas for Medical Sciences"
            }, 
            "investigator": [
                {
                    "last_name": "V. Suzanne Klimberg, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Yihong Kaufmann, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthew E Hardee, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sharp F Malak, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast", 
        "overall_contact": {
            "email": "kaufmannyihong@uams.edu", 
            "last_name": "Yihong Kaufmann, PhD", 
            "phone": "501-257-4811"
        }, 
        "overall_contact_backup": {
            "email": "klimbergsuzanne@uams.edu", 
            "last_name": "V. Suzanne Klimberg, MD", 
            "phone": "501-686-6504"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Arkansas", 
                "last_name": "V. Suzanne Klimberg, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Arkansas", 
                "last_name": "Yihong Kaufmann, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy outcome will be excessive toxicity, which will be defined as a score of 2 or higher using the RTOG (Radiation Therapy Oncology Group) Acute scale of radiation-toxicity criteria when scored on either the 12-day or 30-day assessment time.\nThe RTOG scale ranges from 0-4 with 0 being defined as \"no change\".", 
            "measure": "Excessive radiation toxicity as defined by RTOG (Radiation Therapy Oncology Group) Acute scale of radiation-toxicity criteria", 
            "safety_issue": "No", 
            "time_frame": "12 days and 30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012608"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Arkansas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Arkansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}